RxCheckUp
Acetylcholine release inhibitor and neuromuscular blocking agent

Botox (onabotulinumtoxinA) Letter of Medical Necessity

Botox (onabotulinumtoxinA) is one of the highest-volume prior authorization drugs in the country, with denial patterns varying sharply by indication. A successful Letter of Medical Necessity must precisely document the medical (not cosmetic) indication and prior therapy failures.

Generate a Botox LMN — Free Trial →

FDA-Approved Indications

  • ● chronic migraine (≥15 headache days/month)
  • ● cervical dystonia
  • ● upper and lower limb spasticity
  • ● overactive bladder
  • ● neurogenic detrusor overactivity
  • ● severe primary axillary hyperhidrosis
  • ● blepharospasm
  • ● strabismus

Why Botox Prior Authorization Gets Denied

The most common denial reasons across major payers:

  1. 1. Headache diary not documenting ≥15 headache days/month for 3 months
  2. 2. Failure of two or more preventive medication classes not documented
  3. 3. Use considered cosmetic rather than medical (chronic migraine ICD-10 specificity)
  4. 4. Anticholinergic trial not completed for overactive bladder
  5. 5. Topical antiperspirant trial missing for hyperhidrosis
  6. 6. Quantity (units) exceeds payer limit

What to Include in a Botox Letter of Medical Necessity

For chronic migraine, document a 3-month headache diary showing ≥15 headache days/month with ≥8 migrainous, plus failure or intolerance of at least two preventive classes (e.g., topiramate, propranolol, amitriptyline, CGRP antagonist). For overactive bladder, document anticholinergic trial(s) and urodynamic findings. For spasticity, document Modified Ashworth Scale scores and functional goals.

Key clinical evidence to cite:

  • ✓ PREEMPT 1 & 2 Phase 3 trials — significant reduction in headache days for chronic migraine
  • ✓ EMBRACE trial — efficacy for neurogenic detrusor overactivity
  • ✓ Long-standing Class I evidence for cervical dystonia and spasticity

Relevant guidelines:

  • 📖 AAN 2016 Botulinum Toxin Guidelines
  • 📖 AHS 2021 Migraine Prevention Consensus
  • 📖 AUA 2019 Overactive Bladder Guideline

Botox Prior Authorization Criteria

Standard criteria across major US payers for Botox. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.

Typical step therapy requirements:

  • → Anticholinergic trial not completed for overactive bladder
  • → Topical antiperspirant trial missing for hyperhidrosis

Required documentation:

  • ✓ ICD-10 diagnosis code with specificity
  • ✓ Prior therapy history with dates, doses, and discontinuation reasons
  • ✓ Specialist evaluation (where applicable)
  • ✓ Baseline disease activity or biomarker results
  • ✓ Clinical rationale citing FDA labeling or guidelines

Approval details:

Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.

Payers Covering Botox

RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:

UnitedHealthcareAetnaCignaAnthem BCBSHumanaMedicare Part B

Botox Prior Authorization FAQ

Why was my Botox prior authorization denied?

The most common denial reasons for Botox are: Headache diary not documenting ≥15 headache days/month for 3 months; Failure of two or more preventive medication classes not documented; Use considered cosmetic rather than medical (chronic migraine ICD-10 specificity); Anticholinergic trial not completed for overactive bladder; Topical antiperspirant trial missing for hyperhidrosis; Quantity (units) exceeds payer limit.

What should a Botox Letter of Medical Necessity include?

For chronic migraine, document a 3-month headache diary showing ≥15 headache days/month with ≥8 migrainous, plus failure or intolerance of at least two preventive classes (e.g., topiramate, propranolol, amitriptyline, CGRP antagonist). For overactive bladder, document anticholinergic trial(s) and urodynamic findings. For spasticity, document Modified Ashworth Scale scores and functional goals.

Which payers cover Botox?

Botox is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.